The Next Generation of the GLP-1 Revolution Is Already Underway

The Next Generation of the GLP-1 Revolution Is Already Underway

From The BioMedWire Podcast by podcast@investorbrandnetwork.com

May 15, 2026 · 22 min · Episode 118

About this episode

The episode discusses the advancements in GLP-1 receptor agonists and their impact on obesity and metabolic diseases.

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (Profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history. SureNano is one of the emerging microcap companies operating in the GLP space, forming part of a group of companies leading the way in the GLP-1 space, including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE)…

Topics covered

Keywords

Mentioned in this episode

Organizations: SureNano Science Ltd., GlucaPharm Inc., Eli Lilly and Company, Novo Nordisk A/S, Amgen Inc., Pfizer Inc.

Products: GEP-44

Places: global

More episodes of The BioMedWire Podcast

Explore listener stats, chart rankings, contacts and more on the The BioMedWire Podcast podcast page.